Review
. 2006 Oct;7(10):936-45.
Affiliations
PMID: 17086939
Review
Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor
Brian Tomlinson. Curr Opin Investig Drugs. 2006 Oct.
Abstract
Theratechnologies, under license from Valeant, is developing tesamorelin as a potential vaccine adjuvant and for the potential treatment of wasting, hip fracture recovery, immune disorders, HIV-related lipodystrophy, sleep maintenance insomnia and mild cognitive impairment. Phase III clinical trials for the treatment of HIV-associated lipodystrophy and phase II clinical trials for sleep disorder, chronic obstructive pulmonary disorder, hip fracture and immune system dysfunction are underway. Phase II trials are also assessing the influenza vaccination immune response and cognitive effects of tesamorelin.
PubMed Disclaimer